These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 20460897)
1. New insights into autoimmune cholangitis through animal models. Trauner M; Fickert P; Baghdasaryan A; Claudel T; Halilbasic E; Moustafa T; Wagner M; Zollner G Dig Dis; 2010; 28(1):99-104. PubMed ID: 20460897 [TBL] [Abstract][Full Text] [Related]
2. Animal models for primary sclerosing cholangitis. Vierling JM Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):591-610. PubMed ID: 11492970 [TBL] [Abstract][Full Text] [Related]
3. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810 [TBL] [Abstract][Full Text] [Related]
4. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Trauner M; Fickert P; Halilbasic E; Moustafa T Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069 [TBL] [Abstract][Full Text] [Related]
5. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692 [TBL] [Abstract][Full Text] [Related]
12. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947 [TBL] [Abstract][Full Text] [Related]
13. Immune-mediated cholangiopathies in children: the need to better understand the pathophysiology for finding the future possible treatment targets. Grama A; Mititelu A; Sîrbe C; Benţa G; Pop TL Front Immunol; 2023; 14():1206025. PubMed ID: 37928553 [TBL] [Abstract][Full Text] [Related]
14. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. Chung BK; Guevel BT; Reynolds GM; Gupta Udatha DB; Henriksen EK; Stamataki Z; Hirschfield GM; Karlsen TH; Liaskou E J Autoimmun; 2017 Feb; 77():45-54. PubMed ID: 27784538 [TBL] [Abstract][Full Text] [Related]
17. Will we ever model PSC? - "it's hard to be a PSC model!". Pollheimer MJ; Trauner M; Fickert P Clin Res Hepatol Gastroenterol; 2011 Dec; 35(12):792-804. PubMed ID: 21703962 [TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of primary sclerosing cholangitis. Pollheimer MJ; Halilbasic E; Fickert P; Trauner M Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):727-39. PubMed ID: 22117638 [TBL] [Abstract][Full Text] [Related]
19. Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets. Sato K; Glaser S; Kennedy L; Liangpunsakul S; Meng F; Francis H; Alpini G Expert Opin Ther Targets; 2019 Jun; 23(6):461-472. PubMed ID: 30990740 [TBL] [Abstract][Full Text] [Related]